POSTER: CT-045 Primary Results from OUTREACH: A Phase II Study of Lisocabtagene Maraleucel (Liso-Cel) Administered in the Community Setting As Outpatient or Inpatient Treatment in Patients with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA（2023）
关键词
CAR T-cell therapy,large B-cell lymphoma,outpatient treatment,lisocabtagene maraleucel,phase II
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要